Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Neoplasms 2Skin Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00080535 2018-01-29

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 10 charts
DermatologicLymphoid

Lymphoma, Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00077922 2018-01-23

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
15 enrolled 10 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡